AU2018211985B2 - Tissue-specific Wnt signal enhancing molecules and uses thereof - Google Patents

Tissue-specific Wnt signal enhancing molecules and uses thereof Download PDF

Info

Publication number
AU2018211985B2
AU2018211985B2 AU2018211985A AU2018211985A AU2018211985B2 AU 2018211985 B2 AU2018211985 B2 AU 2018211985B2 AU 2018211985 A AU2018211985 A AU 2018211985A AU 2018211985 A AU2018211985 A AU 2018211985A AU 2018211985 B2 AU2018211985 B2 AU 2018211985B2
Authority
AU
Australia
Prior art keywords
tissue
domain
molecule
wnt
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018211985A
Other languages
English (en)
Other versions
AU2018211985A1 (en
Inventor
Jennifer Jean BRADY
Yang Li
Aaron Ken Sato
Teppei YAMAGUCHI
Wen-Chen Yeh
Zhengjian ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surrozen Operating Inc
Original Assignee
Surrozen Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surrozen Operating Inc filed Critical Surrozen Operating Inc
Publication of AU2018211985A1 publication Critical patent/AU2018211985A1/en
Assigned to Surrozen Operating, Inc. reassignment Surrozen Operating, Inc. Amend patent request/document other than specification (104) Assignors: SURROZEN, INC.
Application granted granted Critical
Publication of AU2018211985B2 publication Critical patent/AU2018211985B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
AU2018211985A 2017-01-26 2018-01-26 Tissue-specific Wnt signal enhancing molecules and uses thereof Active AU2018211985B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762450804P 2017-01-26 2017-01-26
US62/450,804 2017-01-26
US201762487135P 2017-04-19 2017-04-19
US62/487,135 2017-04-19
PCT/US2018/015595 WO2018140821A1 (en) 2017-01-26 2018-01-26 Tissue-specific wnt signal enhancing molecules and uses thereof

Publications (2)

Publication Number Publication Date
AU2018211985A1 AU2018211985A1 (en) 2019-07-18
AU2018211985B2 true AU2018211985B2 (en) 2025-02-13

Family

ID=62978866

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018211985A Active AU2018211985B2 (en) 2017-01-26 2018-01-26 Tissue-specific Wnt signal enhancing molecules and uses thereof

Country Status (7)

Country Link
US (2) US11958891B2 (enExample)
EP (1) EP3574019A4 (enExample)
JP (3) JP7305543B2 (enExample)
CN (1) CN110234662A (enExample)
AU (1) AU2018211985B2 (enExample)
CA (1) CA3050133A1 (enExample)
WO (1) WO2018140821A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング， インコーポレイテッド 抗フリズルド抗体及び使用方法
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
EP3886905A4 (en) * 2018-12-27 2022-08-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. BISPECIFIC ANTIBODY FOR MEMBRANE REMOVAL OF TARGET RECEPTORS
AU2020221797A1 (en) * 2019-02-11 2021-08-12 Surrozen Operating, Inc. Modulation of WNT signalling in ocular disorders
US20220175884A1 (en) * 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
KR20220024460A (ko) * 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
WO2020257758A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
CA3159745A1 (en) * 2019-11-01 2021-05-06 The Regents Of The University Of California Degradation of surface proteins using bispecific binding agent
CA3166963A1 (en) * 2020-01-09 2021-07-15 Kimberly Drenser Neural regeneration with synthetic protein administration
US20230138045A1 (en) * 2020-02-24 2023-05-04 Surrozen Operating, Inc. Wnt super agonists
JP7839789B2 (ja) * 2020-11-10 2026-04-02 ザ スクリプス リサーチ インスティテュート オピオイド治療用抗体
CN116723867A (zh) * 2020-11-16 2023-09-08 瑟罗泽恩奥普瑞汀公司 肝脏特异性Wnt信号增强分子及其用途
WO2022104280A1 (en) * 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
CN116761825A (zh) * 2021-02-03 2023-09-15 基因泰克公司 多特异性结合蛋白降解剂平台及使用方法
CN113307882B (zh) * 2021-05-12 2022-12-20 东北大学 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物
CN113293214A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因wnt2扩增的引物探针及其应用
IL310154A (en) * 2021-07-15 2024-03-01 Diogenx Recombinant variants of r-spondin proteins and their use
US20260185102A1 (en) * 2021-11-02 2026-07-02 Rena Therapeutics Inc. Ligand-binding nucleic acid complex
CN116789843B (zh) * 2022-03-16 2024-09-17 伯桢生物科技(杭州)有限公司 Wnt重组蛋白及其应用
CN116836274B (zh) * 2022-03-23 2024-11-22 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
JP2025525362A (ja) * 2022-06-21 2025-08-05 スロゼン オペレーティング， インコーポレイテッド 角膜障害におけるｗｎｔシグナル伝達の調節
CA3265221A1 (en) * 2022-09-09 2024-03-14 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts TARGETED PD-L1 DEGRADATION
WO2025146152A1 (zh) * 2024-01-04 2025-07-10 上海宝济药业股份有限公司 一种药物组合物及其应用
CN120647751B (zh) * 2025-08-18 2025-12-02 成都迈科康生物科技有限公司 抗人乳头瘤病毒e1蛋白的抗体或其试剂盒和相关应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
EP2305274A1 (en) * 2009-09-21 2011-04-06 Centre National de la Recherche Scientifique (CNRS) Use of WNT stimulators for treating demyelinating diseases
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
US20140044713A1 (en) * 2011-04-14 2014-02-13 Koninklijke Nederlandse Akademie Van Wetenschappen Compounds
WO2017069628A2 (en) * 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
WO2018132572A1 (en) * 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
DE102005035568A1 (de) 2005-07-25 2007-02-01 M-Phasys Gmbh Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
EP2548576B1 (en) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnosis of cancer using anti-desmoglein-3 antibodies
WO2008093646A1 (ja) 2007-02-01 2008-08-07 National University Corporation NARA Institute of Science and Technology Wntシグナル伝達系活性化ペプチド
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US8642339B2 (en) 2009-02-03 2014-02-04 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
WO2010092457A1 (en) 2009-02-10 2010-08-19 Nokia Corporation Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment
MX2012006593A (es) 2009-12-09 2012-06-28 Bayer Pharma AG Anticuerpos anti-c4.4a y usos de los mismos.
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
WO2013071047A1 (en) 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
BR112014020233A2 (pt) 2012-02-28 2017-07-04 Irm Llc seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2014023709A1 (en) 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
BR112016024525A2 (pt) * 2014-04-21 2017-10-10 Abbvie Stemcentrx Llc novos anticorpos anti-rnf43 e métodos de uso
JP6796059B2 (ja) 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｗｎｔシグナリングアゴニスト分子
AU2015340056A1 (en) 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
SG11201708491PA (en) * 2015-04-17 2017-11-29 Merrimack Pharmaceuticals Inc Combination treatments with seribantumab
MY207684A (en) 2015-12-08 2025-03-12 Regeneron Pharma Compositions and methods for internalizing enzymes
US20170349659A1 (en) 2016-06-03 2017-12-07 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
WO2018107116A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
US20200123256A1 (en) 2017-05-02 2020-04-23 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
GB201708330D0 (en) 2017-05-24 2017-07-05 Koninklijke Nederlandse Akademie Van Wetenschappen Fusion protein for enhancing intestinal regeneration
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング， インコーポレイテッド 抗フリズルド抗体及び使用方法
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
AU2019297522B2 (en) 2018-07-05 2026-04-23 Surrozen Operating, Inc. Multi-specific Wnt surrogate molecules and uses thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
US20220064337A1 (en) 2018-12-19 2022-03-03 Surrozen, Inc. Antigen binding formats for receptor complexes
AU2020221797A1 (en) 2019-02-11 2021-08-12 Surrozen Operating, Inc. Modulation of WNT signalling in ocular disorders
WO2020185960A1 (en) 2019-03-11 2020-09-17 Surrozen, Inc. Modulation of wnt signaling in gastrointestinal disorders
US20220175884A1 (en) 2019-04-02 2022-06-09 Surrozen Operating, Inc. Modulation of wnt signaling in auditory disorders
KR20220024460A (ko) 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
US11050604B2 (en) 2019-07-01 2021-06-29 Rampart Communications, Inc. Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation
US20230138045A1 (en) 2020-02-24 2023-05-04 Surrozen Operating, Inc. Wnt super agonists
WO2022104280A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
JP7891006B2 (ja) 2021-03-10 2026-07-15 スロゼン オペレーティング， インコーポレイテッド 胃腸障害におけるｗｎｔシグナル伝達のモジュレーション

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
EP2305274A1 (en) * 2009-09-21 2011-04-06 Centre National de la Recherche Scientifique (CNRS) Use of WNT stimulators for treating demyelinating diseases
US20140044713A1 (en) * 2011-04-14 2014-02-13 Koninklijke Nederlandse Akademie Van Wetenschappen Compounds
WO2013054307A2 (en) * 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
WO2017069628A2 (en) * 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
WO2018132572A1 (en) * 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules

Also Published As

Publication number Publication date
JP7635291B2 (ja) 2025-02-25
AU2018211985A1 (en) 2019-07-18
US11958891B2 (en) 2024-04-16
US20240279303A1 (en) 2024-08-22
JP2025020347A (ja) 2025-02-12
JP2020506701A (ja) 2020-03-05
EP3574019A4 (en) 2021-03-03
JP2023078467A (ja) 2023-06-06
EP3574019A1 (en) 2019-12-04
WO2018140821A1 (en) 2018-08-02
JP7305543B2 (ja) 2023-07-10
CA3050133A1 (en) 2018-08-02
CN110234662A (zh) 2019-09-13
US20200048324A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
JP7657249B2 (ja) 治療用ヌクレアーゼ組成物および方法
US20230340160A1 (en) Bispecific t cell activating antigen binding molecules
CN110234662A (zh) 组织特异性wnt信号增强分子和其用途
KR102890653B1 (ko) 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
CN110719920B (zh) 蛋白质异二聚体及其用途
KR101901458B1 (ko) Ｔｃｒ 복합체 면역치료제
AU2016329120B2 (en) Bispecific antibodies specific for a costimulatory TNF receptor
KR102648966B1 (ko) Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
CN112654363A (zh) 组织特异性wnt信号增强分子和其用途
CN109311973A (zh) 含有c端融合的tnf家族配体三聚体的抗原结合分子
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
HK1259474A1 (zh) 新的免疫缀合物
KR20150122761A (ko) Ｔ 세포 활성화 항원 결합 분자
KR20160032041A (ko) 단백질 약물의 불활성화를 위한 항체 로커
KR20230060501A (ko) 바이러스 치료제에서 다방성 생체이동을 위한 재료 및 방법
KR20230165829A (ko) 이중특이적 분자 및 관련 조성물 및 방법
RU2840013C1 (ru) Способ получения конъюгата антитело-лекарственное средство на основе эрибулина

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SURROZEN OPERATING, INC.

Free format text: FORMER NAME(S): SURROZEN, INC.

FGA Letters patent sealed or granted (standard patent)